Institution
University of Ioannina
Education•Ioannina, Greece•
About: University of Ioannina is a education organization based out in Ioannina, Greece. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 7654 authors who have published 20594 publications receiving 671560 citations. The organization is also known as: Panepistimio Ioanninon.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A comparison between the proposed methods and the conventional multiresidue solid-phase extraction revealed that the proposed technique(s) can be reliably used for sunscreen residue measurement in water samples with satisfactory results.
160 citations
••
29 Jan 2014
TL;DR: In this article, a search for new physics was performed based on events with jets and a pair of isolated, same-sign leptons, and the results were obtained using a sample of proton-proton collision data collected by the CMS experiment at a centre-of-mass energy of 8 TeV at the LHC, corresponding to an integrated luminosity of 19.5 fb−1.
Abstract: A search for new physics is performed based on events with jets and a pair of isolated, same-sign leptons. The results are obtained using a sample of proton-proton collision data collected by the CMS experiment at a centre-of-mass energy of 8 TeV at the LHC, corresponding to an integrated luminosity of 19.5 fb−1. In order to be sensitive to a wide variety of possible signals beyond the standard model, multiple search regions defined by the missing transverse energy, the hadronic energy, the number of jets and b-quark jets, and the transverse momenta of the leptons in the events are considered. No excess above the standard model background expectation is observed and constraints are set on a number of models for new physics, as well as on the same-sign top-quark pair and quadruple-top-quark production cross sections. Information on event selection efficiencies is also provided, so that the results can be used to confront an even broader class of new physics models.
160 citations
••
TL;DR: The use of conjoint analysis in exploring Greek consumers' willingness to pay (WTP) for PDO apples from the area of Zagora, Central Greece, has been selected as one of the most appropriate approaches to that target as discussed by the authors.
Abstract: The adoption of different quality assurance schemes, such as the Protected Denomination of Origin/Geographical Indication (PDO/PGI) by the European Union, has been a response to the growing demand for certified quality food products among consumers. Tries to offer some more insights into the effectiveness of the PDO scheme and its acceptance by the consumer. The use of conjoint analysis in exploring Greek consumers’ willingness to pay (WTP) for PDO apples from the area of Zagora, Central Greece, has been selected as one of the most appropriate approaches to that target. Opens with a brief theoretical background presentation on the concepts of food quality and labelling. Proceeds with a detailed description of the research methodology, focusing on the WTP measurement method through the use of conjoint analysis, the identification of segments based on the importance consumers attach to the PDO label and the development of their profiles. Finally, concludes with some thoughts regarding the managerial implications of the findings, the limitations of the survey and the suggested research extensions.
159 citations
••
TL;DR: The aim of this study was to estimate the magnitude of survival and disease progression benefits with the use of different regimens in patients with advanced colorectal cancer by using multiple-treatment meta-analysis methodology.
Abstract: Summary Background Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental benefits across diverse regimens is less clear. The aim of our study was to estimate the magnitude of survival and disease progression benefits with the use of different regimens in patients with advanced colorectal cancer. Methods We systematically reviewed randomised trials comparing systemic treatment regimens in advanced colorectal cancer. Treatment was categorised by use of or no use of fluorouracil-based regimens, irinotecan, oxaliplatin, bevacizumab, and cetuximab. We used multiple-treatment meta-analysis methodology to combine information from direct comparisons (ie, treatments compared within a randomised trial) and indirect comparisons (ie, treatments compared between trials by combining results on how effective they are against a common comparator treatment) of different chemotherapy regimens. The primary endpoint was death and the secondary endpoint was disease progression. Monte Carlo simulations were used to establish which regimen offered the most benefit for these endpoints. We did analyses of all trials and analysed separately trials that studied first-line treatments and non-first-line treatments. Findings 242 trials published in 1967–2007 (N=56 677 patients) involved 137 different chemotherapy regimens. 37 of these trials were eligible for the multiple-treatment meta-analysis, according to our categorisation, including 47 comparisons of data on death (N=13 875 patients) and 48 comparisons of data on disease progression (N=15 158 patients). Compared with fluorouracil plus leucovorin alone, the risk of death was most decreased with the addition of irinotecan plus bevacizumab (hazard ratio [HR] 0·60, 95% credibility intervals (CrI) 0·44–0·84) and considerable benefits were also noted with addition of irinotecan plus oxaliplatin (HR 0·72 [95% CrI 0·54–0·97]); oxaliplatin plus bevacizumab (HR 0·72 [0·57–0·90]); bevacizumab alone (HR 0·78 [0·60–1·03]); and oxaliplatin alone (HR 0·87 [0·78–0·98]). The disease progression benefits were even more prominent for the addition of irinotecan plus bevacizumab (HR 0·41 [0·28–0·60]); irinotecan plus oxaliplatin (0·53 [0·38–0·73]); oxaliplatin plus bevacizumab (0·46 [0·34–0·61]); bevacizumab alone (0·56 [0·41–0·76]); oxaliplatin alone (0·64 [0·56–0·73]); irinotecan plus cetuximab (HR 0·62 [0·42–0·92]); and irinotecan alone (HR 0·73 [0·65–0·82]). Findings were similar for first-line and non-first-line treatment analyses although data were sparse for non-first-line treatment analyses. Compared with a patient with an anticipated 1-year survival who is treated with fluorouracil and leucovorin, the absolute survival benefit is estimated at 8 months' prolongation with addition of irinotecan plus bevacizumab, 4·7 months' prolongation with addition of oxaliplatin plus bevacizumab or irinotecan plus oxaliplatin, and 1–1·8 months' prolongation with addition of irinotecan alone or oxaliplatin alone. Interpretation Distinct incremental benefits are noted for diverse chemotherapy regimens in patients with advanced colorectal cancer, with more prominent effects on disease progression than on death. More data are needed at least for the newest drugs to estimate more accurately the magnitude of the benefit derived from their use.
159 citations
••
TL;DR: A model to survey the current status and gaps in evidence in the field of DNA repair genes and cancer susceptibility, may indicate potential pleiotropic activity of genes and gene pathways, and may offer mechanistic insights in carcinogenesis is offered.
Abstract: This work was made possible by a grant to ECNIS (Environmental Cancer
Risk, Nutrition and Individual Susceptibility), a network of excellence operating
within the European Union 6th Framework Program, Priority 5: “Food
Quality and Safety” (contract no. 513943), and by a grant of the compagnia
di San Paolo, of the Italian Association for Cancer Research, Italy, and of the
Piedmont Region Progetti di Ricerca Sanitaria Finalizzata. F. K. Kavvoura is
supported by a PENED training grant cofi nanced by EU — European Social
Fund (75%) and the Greek Ministry of Development – General Secretariat of
Research and Technology (25%).
159 citations
Authors
Showing all 7724 results
Name | H-index | Papers | Citations |
---|---|---|---|
John P. A. Ioannidis | 185 | 1311 | 193612 |
Kay-Tee Khaw | 174 | 1389 | 138782 |
Elio Riboli | 158 | 1136 | 110499 |
Mercouri G. Kanatzidis | 152 | 1854 | 113022 |
Dimitrios Trichopoulos | 135 | 818 | 84992 |
Gyorgy Vesztergombi | 133 | 1444 | 94821 |
Niki Saoulidou | 132 | 1065 | 81154 |
Apostolos Panagiotou | 132 | 1370 | 88647 |
Ioannis Evangelou | 131 | 1225 | 82178 |
Ioannis Papadopoulos | 129 | 1201 | 85576 |
Nikolaos Manthos | 129 | 1256 | 81865 |
Panagiotis Kokkas | 128 | 1234 | 81051 |
Costas Foudas | 128 | 1112 | 83048 |
Zoltan Szillasi | 128 | 1214 | 84392 |
Matthias Schröder | 126 | 1421 | 82990 |